Spots Global Cancer Trial Database for locally advanced malignant solid neoplasm

Every month we try and update this database with for locally advanced malignant solid neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer	NCT05058339	Advanced Malign... COVID-19 Infect... Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Hemat... Recurrent Malig...	Survey Administ...	18 Years -	M.D. Anderson Cancer Center
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	NCT03284385	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Stage III Renal... Stage IV Renal ...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	NCT01902173	Hematopoietic a... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Stage IIIC Cuta... Stage IV Cutane... Unresectable Ma... Unresectable Me...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Magnetic Resona... Trametinib Dime... Uprosertib	18 Years -	National Cancer Institute (NCI)
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors	NCT04771520	Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Metastatic Prim... Metastatic Sarc... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Prognostic Stag... Prognostic Stag... Stage IIIC Colo... Stage IIIC Lung... Stage IV Colore... Stage IV Lung C... Stage IVA Color... Stage IVA Lung ... Stage IVB Color... Stage IVB Lung ... Stage IVC Color...	Avapritinib	18 Years -	M.D. Anderson Cancer Center
PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning	NCT04889144	Locally Advance... Metastatic Mali...	Communication I... Best Practice Questionnaire A...	18 Years -	Fred Hutchinson Cancer Center
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial	NCT05554380	Locally Advance... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Magnetic Resona... Paclitaxel	18 Years -	National Cancer Institute (NCI)
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor	NCT04800627	Locally Advance... Metastatic Mali... Unresectable Ma...	Pembrolizumab Pevonedistat	18 Years -	M.D. Anderson Cancer Center
PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning	NCT04889144	Locally Advance... Metastatic Mali...	Communication I... Best Practice Questionnaire A...	18 Years -	Fred Hutchinson Cancer Center
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors	NCT03682289	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Metastatic Urot... Metastatic Panc... Stage III Pancr... Stage III Renal... Stage IV Pancre... Stage IV Renal ... Endometrial Can... Metastatic Cast...	Ceralasertib Olaparib Durvalumab	18 Years -	University of California, San Francisco
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	NCT05564377	Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma...	Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib	-	National Cancer Institute (NCI)
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	NCT04879121	Locally Advance... Metastatic Mali...	Larotrectinib S...	16 Years -	M.D. Anderson Cancer Center
Testing the Safety of CB-5339 in Patients With Cancer	NCT04372641	Aggressive Non-... Indolent Non-Ho... Locally Advance... Metastatic Mali...	p97 Inhibitor C...	18 Years -	National Cancer Institute (NCI)
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors	NCT05010096	Locally Advance... Metastatic Mali... Metastatic Mali... Recurrent Malig...	Copanlisib Elimusertib	18 Years -	M.D. Anderson Cancer Center
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer	NCT01949662	Advanced Cancer...	Lorazepam Placebo Haloperidol dec... Questionnaires	18 Years -	M.D. Anderson Cancer Center
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors	NCT05010096	Locally Advance... Metastatic Mali... Metastatic Mali... Recurrent Malig...	Copanlisib Elimusertib	18 Years -	M.D. Anderson Cancer Center
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer	NCT02321501	ALK Positive Locally Advance... Metastatic Mali... ROS1 Gene Rearr... Stage IIIB Lung... Stage IV Lung N...	Ceritinib Everolimus Laboratory Biom... Pharmacological...	18 Years -	M.D. Anderson Cancer Center
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	NCT03284385	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Stage III Renal... Stage IV Renal ...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer	NCT02595866	AIDS-Related No... Clinical Stage ... Clinical Stage ... Hepatocellular ... HIV Infection Kaposi Sarcoma Locally Advance... Locally Advance... Metastatic Lung... Metastatic Mali... Metastatic Mela... Non-Hodgkin Lym... Recurrent Class... Recurrent Malig... Refractory Clas... Refractory Mali... Stage III Lung ... Stage IV Lung C... Unresectable Me...	Antiretroviral ... Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer	NCT05058339	Advanced Malign... COVID-19 Infect... Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Hemat... Recurrent Malig...	Survey Administ...	18 Years -	M.D. Anderson Cancer Center
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma	NCT04387071	Locally Advance... Metastatic Panc... Stage IV Pancre... Unresectable Ma...	Agonistic Anti-... VLP-encapsulate...	18 Years -	University of Southern California
Adoption of Audio Recording in the Outpatient Supportive Care Center	NCT04871477	Advanced Malign... Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Malig...	Communication I... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers	NCT03868423	Advanced Malign... ALK Fusion Prot... ALK Gene Amplif... ALK Gene Mutati... Locally Advance... Metastatic Mali... Metastatic Mali... Metastatic Mali... ROS1 Fusion Pos... ROS1 Gene Ampli... ROS1 Gene Mutat...	Brigatinib Laboratory Biom... Quality-of-Life... Questionnaire A...	18 Years -	Ohio State University Comprehensive Cancer Center
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma	NCT04387071	Locally Advance... Metastatic Panc... Stage IV Pancre... Unresectable Ma...	Agonistic Anti-... VLP-encapsulate...	18 Years -	University of Southern California
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations	NCT04550494	Advanced Pancre... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HER2-Positive B... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Brea... Metastatic Gast... Metastatic Mali... Metastatic Ovar... Metastatic Panc... Metastatic Pros... Platinum-Sensit... Stage II Pancre... Stage III Ovari... Stage III Pancr... Stage III Prost... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Talazoparib	18 Years -	National Cancer Institute (NCI)
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma	NCT05472220	Solid Tumors, A... PIK3CA Mutation... PIK3CA Mutation Human Papilloma... HPV-Related Squ... Human Papilloma... Locally Advance... Metastatic Mali...	Alpelisib Carboplatin Hyperpolarized ... Continuous Gluc...	18 Years -	University of California, San Francisco
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors	NCT06364410	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Mali... Unresectable Ga... Unresectable Ga... Unresectable Ma...	Azenosertib Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit	NCT05091632	Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Malig...	Electroencephal... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors	NCT06364410	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Mali... Unresectable Ga... Unresectable Ga... Unresectable Ma...	Azenosertib Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors	NCT03682289	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Metastatic Urot... Metastatic Panc... Stage III Pancr... Stage III Renal... Stage IV Pancre... Stage IV Renal ... Endometrial Can... Metastatic Cast...	Ceralasertib Olaparib Durvalumab	18 Years -	University of California, San Francisco
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer	NCT01949662	Advanced Cancer...	Lorazepam Placebo Haloperidol dec... Questionnaires	18 Years -	M.D. Anderson Cancer Center
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types	NCT06075524	Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Lung... Metastatic Mali... Metastatic Mela... Stage III Lung ... Stage IV Lung C...	Biospecimen Col... Electronic Heal...	18 Years -	Mayo Clinic

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: